BUILDING A PORTFOLIO .....ADVICE MOST WELCOME

This is not a portfolio this stocks are with me because of losses in trading not investing.
gradually after some losses i changed my mind and to stop losses holding following stocks .
we will turn them in to portfolio by booking profit or averaging stocks to cover loss.

1.sun pharma 12.34% ....stongest stock in indian pharma thinking will benefit from ranbaxy
merger target pries 1241 ......and will think after that.....no stop loss

1.Morgan Stanley target 1241.00 on 01-04-2015
2. motilal oswale target 1220.00 0n 09 -03 -2015
3.nirmal bang neural


2.yes bank 21.22% thinking will benefit from nifty enclosure ...they are starting asset management business .....stock showed resilience below 800... so bought near it

1.Deutsche Bank target 950 on 30-03-2015
2.JP Morgan target 950 on 27-01-2015
3. Macquarie target 950 on 09-01-2015
4.Goldman sache downgraded .....Removed from Asia Pacific Buy List .....Long-term growth intact; down to Neutral on balanced risk-reward target was 880 so target met.

5.14 Indian brokers have buy calls target @nearly 900-1000/-
no negative or downgraded broker report if any suggest me.
about yes bank in dawn market more shots were in yes bank targeting 770....



3.Gabriel India 13.65% Return On Capital Employed 11.15 .....ROE 16.15
Debt Equity Ratio .23


4. chamanlal sethia export ltd 1.11% exporter of basmati rice only 1.11 % because i got that much only no sellers......


5.inox leisure 10.42% thinking will do well after inox wind ipo listing
1.icici direct @181 target 240
2. motilal oswal @ 181 target 240
3.Reliance MF buys 1.07 mn shares in INOX Leisure @ 170
4.Goldman Sachs India Fund bought 1.25 million shares @175
5.Macquarie Asia New Stars Fund bought 592,392 @182
6.Norges Bank on a/c Govt Pension Fund Global bought 1.25 mln
7.https://www.livemint.com/Money/Rn2LNGqNbxVIdYw7G6EyiK/Multiplex-stocks-in-need-of-more-hits.html



6.mahindra cie 10.78% icici direct target 260 .... its bouth @220 after avrg price is 200
so in profit


7.herculas hoist 30.47% debt free company Return on equity: 11.84% Return on capital employed: 13.02% pramoted by shishir bajaj bouth @ 200 just thinking to avrage and cover loss...
Return on Equity
10 YEARS:12.17%
5 YEARS:-0.14%
3 YEARS:-12.39%

Compounded Profit Growth

10 YEARS:12.17%

5 YEARS:-0.14%

3 YEARS:-12.39%

TTM:-30.06%

thinking to add this stocks 1. premier explosive
2. auro pharma
3 . bpcl
4. ashok layland
5.v guard
6. dhfl
7.hsil
8.ifb indus
9.atul auto
10.axis bank
i will share all my information .....if you have any info please share don't hesitate

 

Think again about ChamanLal Sethia , Hercules Hoists and Mahindra CIE.

How about slowly adding "Gujarat Minerals Development Corporation Limited" (GMDC) around its Book Value or may be VST Tillers at current level?

Goodluck

 

There are many companies which have corrected sharply...so look at few blue chips like ITC, ICICI, PSU banks, MM Finance, well managed mid cap IT ... I really don't know much about Chamanlal Sethia, Hercules but don't put more than 10% in any single stock and if you put a high amount be damn sure its going to do well....Mahindra CIE has a strong pedigree and wide reach, Yes Bank is also a good stock... ...at least try to ensure that 50% of your portfolio are blue-chips, quality mid caps

 

1. Buy Chaman Lal Setia Exp; tgt of Rs 78: Firstcall Research

Read more at: https://www.moneycontrol.com/news/recommendations/buy-chaman-lal-setia-exp-tgtrs-78-firstcall-research_1341427.html?utm_source=ref_article

2. Promoter holding: 74.39 % Current Price: 74.30
Return on capital employed: 27.38%
Return on equity: 30.73%
Debt to equity: 0.91
Stock P/E: 3.92
Stock is trading at 0.88 times its book value Book Value: 84.16
PEG Ratio: 0.10
Dividend Yield: 2.33%

3.Compounded Profit Growth
10 YEARS:33.01 5 YEARS:37.73% 3 YEARS:44.70%


........AND yes theme is lacking can't figure out future of rice industry or this stock.
will wait till results .....still in 12% profit ..............waiting for your replay.....

 

thanks for advice ................agree with you herculas hoist is only loss making stock thinking to cover loss and then will decide ....few days to result will get target met hope so

:'( MAHINDRA CIE :'(
Return on equity: -11.56% Return on capital employed: -0.89% Debt to equity: 1.04
Promoter holding: 60.56%
The company has delivered a poor growth of 2.92% over past five years.

1.Icici Prudential Mutual F buy @ 234.95 on 21/01/2015
2. Government Of Singapore buy @ 230.50 on 19/01/2015
3.motilal oswal on 12 February 2015 not rated 3QFY15 revenue under pressure But turnaround on track
4.Buy Mahindra CIE; target of Rs 260: ICICIDirect.com

Read more at: https://www.moneycontrol.com/news/recommendations/buy-mahindra-cie-targetrs-260-icicidirectcom_1332749.html?utm_source=ref_articleMahindra CIE Auto is a unique case of valuation considering the massive

turnaround possibilities. We expect utilisation levels to improve leading to
EBIT margins rising to 8% and RoCE expansion to ~15% in FY17E. We
expect dividend payout of ~30%, in line with CIE’s philosophy of high
dividend payouts (~30-50%). CFOs are also likely to balloon to ~| 700-
800 crore (FY17E). We value MCI at 10x FY17E EV/EBITDA multiple
(~25% discount to Bharat Forge), considering its steady turnaround in
operations. Our target price of | 260 implies an upside of ~29%. We
continue to recommend BUY.

there are no negative :'(for mahindra cie other than pe roe roce all parameters are not good.
if i swich to another any midcap stock good moat and high value .

this may correct and i don't want more pain :-\ i saw in mahindra cie which was down to 184
so saw dawnside like to see upside ;D (atleast some)

 

INOX puts up a good show in the December quarter

Read more at: https://www.livemint.com/Money/bQE9fUgjVfXAFAdkaLA51J/INOX-puts-up-a-good-show-in-the-December-quarter.html?utm_source=copy

 

there can be no metrics for Mahindra CIE for last 5 years because it came into existence last year. It has been formed after Mahindra Forgings, Mahindra Ugine merged with CIE Automotive of Spain. I agree its not a very profitable company because Mahindra Group was facing many challenges in their automotive business. With the merger and new promoter coming in there is likelihood of turnaround as the promoter group streamlines business, benefits of synergies in Europe arise. So I think this is good turnaround. The market has factored the good news in the stock price but I think the company in its new form is very promising, especially because it has access to large European markets.
Agri based stocks have always been wealth destructive in general, whereas agro-chemical and input stocks have created more wealth. I generally do not recommend such stocks because of their direct impact on soil fertility , environment, etc. So if you want to invest in agri related stocks invest in agri input not agri produce stocks.

 

One stock that has seen strong gains over the past one year has been Mahindra CIE. The stock has risen 20 % in the last 6 months alone and a whopping 166 % in the last one year. Bloomberg TV India’s, Swati Khandelwal Jain caught up with Hemant Luthra, Chairman, Mahindra CIE and began by asking him what is working for the company.

https://www.btvin.com/videos/watch/11494/mahindra-cie's-winning-strategy

​

yes.... you are right market is factoring most of the gains whopping 166% in one year ..... :

 

ADDED AUROBINDO PHARMA 10.64 % OF PORTFOLIO

 

Why? Stock is up 6% today. Is it correct time to add? What is the reason? Pl explain reason. I also want to add a pharma stock. But I am thinking of JB Chem as it is cheap.

 

ok done

 

Auro pharma
Citi say's on 12 March 2015
Management Meeting Takeaways: Improving US Pipeline, EU
Turnaround to Drive Growth & Re-rating. Top Mid Cap Pick.
Buy Price (12 Mar 15) Rs 1,117.25
Target price Rs 1,945.00
Expected share price return 74.1%

Valuation
We value Aurobindo at Rs 1,945. Given that pharma is a growth sector, we use P/E
as our primary method to value the base business of pharma companies. We value
Aurobindo's core earnings at 20x Mar'17E FDEPS - a c15% discount to the target
multiple of 24x that we use for sector leaders and in line with the 18-20x range we
use for its mid-cap peers such as Glenmark and Cadila. Aurobindo now compares
favorably to its mid-cap peers on multiple operating and financial parameters and
should therefore re-rate to trade in line with the latter over the next few quarters, in
or view. At 20x Mar'17E FDEPS, we arrive at a target price of Rs1,945 per share.

Risks
The key risks that could impede the shares from reaching our target price are: (1)
Execution hiccups in turning around the acquired EU businesses from Actavis; (2)
Inability to scale up utilization levels at the Hyderabad SEZ, as planned; (3) Any
delay in products approvals especially in the US could hurt scale-up.

Bank of America Merrill Lynch
on 20-02-2015 Buy with Target .... 1430.00

Aurobindo Pharma gets USFDA approval for Sildenafil injection;
Maintain BUY with PT of Rs1,412 by india nivesh

yes .....you are right it is very danger to catch a running train .
i have read recent sec report on pharma secter top pick of all is aurobindo and sun pharma .
sun pharma i already have . I am not comfortable with small pharma co and there valuation market offering to them.i was waiting to cut dawn my loss making stocks and to add this ...
auro was near all time high .....i thought if it makes new high day traders will take it to new high...and one may Never get it .......look at natco ....aarti....shilpa..etc
i strongly believe result of pharma co will be best .

bouth @ 1288

 

always keep in mind any stock which open and close at days high it will make higher high......
technical analyst always see what was closing pries of a stock ........... auro is bullish for coming days....

 

Thanks. Good insight. I am feeling more confident about Auro.

 

Aurobindo Pharma Ltd has informed BSE regarding a Press Release dated April 04, 2015 titled "Aurobindo Pharma receives USFDA Approval for Sildenafil Injection

what will be impact of this news ??????

 

https://www.business-standard.com/article/companies/aurobindo-pharma-regaining-traction-115031700968_1.html

analysts as Ranjit Kapadia at Centrum Broking have target price of Rs 1,380,
HSBC's have a target price of Rs 1,586
and those most bullish as Citi have target price of Rs 1,945.

 

Aurobindo Pharma Target Price: Rs 1707 Potential upside: 54% Rationale: With its multiple growth levers in place is set to witness a rampant growth phase over FY15-FY19E dependent on unfolding of its heavily ramped up ADNA portfolio in US, foray into US OTC markets, strong footprint in the EU markets, a CS portfolio targeting addressable market of USD 500mn, a germinating injectables pipeline and a broad spectrum peptides business unfolding in longer run, providing a stark essence to Aurobindo's non-institutional business.

Read more at: https://www.moneycontrol.com/news/stocks-views/looking-for-18-54-profit-5-pharma-stocks-forhealthy-portfolio_1329457-10175.html?utm_source=ref_article

 

WHAT IS STORY IN APOLLO TYRE ??? : VOLUME BASED BUYING SEEN ON 31 MARCH 2015 HIGHEST :-\ IN A YEAR ???

 

Retain cautious view on M&M Fin :'(; like Yes Bank : Nomura

Read more at: https://www.moneycontrol.com/news/marketoutlook/retaincautiousviewmmfinlikeyesbanknomura_1350616.html?utm_source=ref_article